Fosamax Osteonecrosis of the Jaw Prognosis: Long term outcome of Osteonecrosis of the Jaw after Fosamax exposure

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Prevention to Specific Risks

The legacy of general health and science communication has long emphasized broad preventive strategies, such as the use of low-dose aspirin in older adults with cardiovascular risk factors, as illustrated by recent large-scale trials. These efforts aim to translate population-level data into actionable guidance for chronic disease management. However, the scope of health information must also address unintended consequences of widely prescribed medications, particularly when long-term exposure reveals rare but serious adverse effects. This transition from general preventive contexts to specific pharmacovigilance concerns is exemplified by the shift in focus toward bisphosphonate therapies, such as Fosamax, which are commonly used for osteoporosis. While these drugs effectively reduce fracture risk, prolonged use has been associated with osteonecrosis of the jaw (ONJ), a condition that raises critical questions about prognosis and long-term outcomes. Understanding the trajectory of ONJ following Fosamax exposure requires careful consideration of patient history, duration of therapy, and comorbid factors. This pivot from broad health maintenance to targeted risk assessment underscores the need for nuanced communication that balances therapeutic benefits against potential harms, particularly in occupational settings where cumulative exposure may amplify concerns.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a recognized adverse effect associated with bisphosphonate use, including Fosamax, and can occur spontaneously or in conjunction with dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition involves bone death in the jaw and is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The prognosis for patients who develop ONJ after Fosamax exposure varies. According to labeling information, the time to onset of symptoms after starting the drug can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the medication, though a subset may have recurrence of symptoms if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that for many patients, stopping Fosamax can lead to resolution of ONJ, but the condition may persist or recur in some cases.

Risk Factors and Long-Term Outcomes

Risk factors for developing ONJ include invasive dental procedures such as tooth extraction, dental implants, or boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Population-level data from a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink provides further insight into long-term outcomes. The study found that among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that while the relative risk increases with longer exposure, the absolute risk of developing ONJ remains small, and prognosis improves after stopping the medication.

Mechanisms and Warning Adequacy

The mechanistic pathways linking Fosamax to ONJ involve the drug's effects on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast activity, reducing bone turnover. In the jawbone, this suppression of remodeling may impair the ability to heal from microdamage or dental procedures, leading to necrosis. A multiscale characterization of jawbone tissue has been conducted to better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research aims to clarify why the jaw is particularly susceptible to this adverse effect. Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw under warnings and precautions. It notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, the long-term risk-benefit balance requires individual assessment.

Timeline and Prognosis Summary

The timeline between exposure and documented harm varies. Symptoms can appear as early as one day after starting Fosamax or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with duration of use, with significant elevations seen after 2-3 years and further increases after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). After discontinuation, the risk diminishes, and most patients experience symptom relief (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702/). In summary, the long-term outcome of ONJ after Fosamax exposure is generally favorable for most patients, with symptom resolution upon drug cessation. However, a subset of patients may experience recurrence if rechallenged. The absolute risk remains low, but increases with longer treatment duration. Adequate warnings are present in the labeling, and risk mitigation strategies, such as dental evaluation before starting therapy and consideration of drug holidays, are recommended.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the prognosis for osteonecrosis of the jaw after stopping Fosamax?

Most patients experience relief of symptoms after discontinuing Fosamax, though a subset may have recurrence if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The absolute risk of ONJ is low, approximately 0.05% after 5 years, and diminishes after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How long does it take for Fosamax to cause osteonecrosis of the jaw?

Symptoms can appear as early as one day after starting Fosamax or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of use, with significant elevations after 2-3 years and further increases after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing osteonecrosis of the jaw from Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.